Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28704032 | 0.89 | KDM4E (0.32) | — | |
| SCHEMBL3500438 | 0.87 | TNK2 (0.44) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL739210 | 0.81 | DHFR (0.45) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL7366055 | 0.80 | DHFR (0.40) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL4819647 | 0.80 | DHFR (0.40) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL222919 | 0.79 | MEN1 (0.43) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL14852899 | 0.79 | TNK2 (0.46) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL15093765 | 0.79 | MEN1 (0.43) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL8080838 | 0.79 | TNK2 (0.40) | DHFRTNK2MEN1KMT2AKDM4C | |
| SCHEMBL813805 | 0.79 | NPC1 (0.46) | DHFRTNK2MEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | claimed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | claimed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | claimed |
| JP-2005536450-A | — | — | 2005-12-02 | — | — | JP | claimed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| EP-0463488-B2 | O-Benzyl oxime ethers and fungicides containing them | BASF AG (DE) | 2004-04-21 | — | — | EP | claimed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | claimed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-4201782-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1980-05-06 | — | — | US | claimed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-3783074-A1 | COPOLYMER FOR ANTIFOULING COATING COMPOSITION AND ANTIFOULING COATING COMPOSITION CONTAINING SAID COPOLYMER | Nitto Kasei Co., Ltd. (JP) | 2021-02-24 | — | — | EP | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| CN-111886305-A | Copolymer for antifouling paint composition, and antifouling paint composition comprising same | 日东化成株式会社 | 2020-11-03 | — | — | CN | disclosed |
| WO-2019203182-A1 | COPOLYMER FOR ANTIFOULING COATING COMPOSITION AND ANTIFOULING COATING COMPOSITION CONTAINING SAID COPOLYMER | 日東化成株式会社 | 2019-10-24 | — | — | WO | disclosed |
| US-3933900-A | ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933895-A | PROSTAGLANDINS, ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933897-A | ANTIULCER, ASTHMA, RENAL DYSFUNCTION | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933899-A | ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933898-A | ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3931289-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | DHFR 730/4885TNK2 778/4885MEN1 4405/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | DHFR 1809/4885TNK2 2551/4885MEN1 2330/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | DHFR 1462/4885TNK2 2820/4885MEN1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.